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Long non-coding RNAs (lncRNAs) play crucial roles in human physiology, and have been
found to be associated with various cancers. Transcribed ultraconserved regions (T-
UCRs) are a subgroup of lncRNAs conserved in several species, and are often located in
cancer-related regions. Breast cancer is the most common cancer in women worldwide
and the leading cause of female cancer deaths. We investigated the association of
genetic variants in lncRNA and T-UCR regions with breast cancer risk to uncover
candidate loci for further analysis. Our focus was on low-penetrance variants that can
be discovered in a large dataset. We selected 565 regions of lncRNAs and T-UCRs
that are expressed in breast or breast cancer tissue, or show expression correlation to
major breast cancer associated genes. We studied the association of single nucleotide
polymorphisms (SNPs) in these regions with breast cancer risk in the 122970 case
samples and 105974 controls of the Breast Cancer Association Consortium’s genome-
wide data, and also by in silico functional analyses using Integrated Expression
Quantitative trait and in silico prediction of GWAS targets (INQUISIT) and expression
quantitative trait loci (eQTL) analysis. The eQTL analysis was carried out using the
METABRIC dataset and analyses from GTEx and ncRNA eQTL databases. We found
putative breast cancer risk variants (p < 1 × 10−5) targeting the lncRNA GABPB1-AS1
in INQUISIT and eQTL analysis. In addition, putative breast cancer risk associated SNPs
(p < 1 × 10−5) in the region of two T-UCRs, uc.184 and uc.313, located in protein
coding genes CPEB4 and TIAL1, respectively, targeted these genes in INQUISIT and
in eQTL analysis. Other non-coding regions containing SNPs with the defined p-value
and highly significant false discovery rate (FDR) for breast cancer risk association were
discovered that may warrant further studies. These results suggest candidate lncRNA
loci for further research on breast cancer risk and the molecular mechanisms.
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INTRODUCTION
About 70–90% of the human genome is transcribed (Guttman et al., 2009; Mercer et al., 2009). The
protein coding RNAs account for only a small fraction of all the transcripts, while non-coding RNAs
(ncRNA) cover 95% (Dermitzakis et al., 2005; Kapranov et al., 2007; Mattick, 2009). These include
long non-coding RNAs (lncRNAs), defined as ncRNAs with over 200 nucleotides. They participate
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in various biological processes, including differentiation, immune
response and metabolism (Kretz et al., 2013; Hung et al., 2014;
Wang et al., 2014) as well as in pathogenic processes, such as the
development and progression of cancer (Gupta et al., 2010; Yang
et al., 2013; Xing et al., 2014). Their expression exhibits cell type
specificity and responds to various stimuli, suggesting a rigorous
transcriptional regulation (Wang and Chang, 2011).
A curious subclass of lncRNAs are the ultraconserved regions
(UCRs). These are stretches of DNA expanding over 200
nucleotides that are absolutely conserved between orthologous
regions in human, mouse and rat (Bejerano et al., 2004). There
exist 481 such regions spread across the human genome, and 93%
of the UCRs are transcribed in at least one normal human tissue
(Calin et al., 2007). However, the study of T-UCR expression is
complicated: based on annotation compiled by Mestdagh et al.
(2010), 38.7% of the 481 T-UCRs are intergenic and 57.4% of the
481 T-UCRs are located in protein coding genes (42.6% intronic,
4.2% exonic, 5% partly exonic, and 5.6% exon containing), and
3.9% of T-UCRs lack an explicit gene-related annotation, because
of the host gene splice variants. For these intragenic T-UCRs, it
is difficult to define if the expression signal/measurement comes
from the T-UCR or from the host gene. Mestdagh et al. (2010)
studied this question in neuroblastoma tissue and found 237
T-UCRs to be independently expressed while the expression
of the remaining 244 T-UCRs was inseparable from the host
gene expression, either because the T-UCR was expressed as
a part of the host gene transcript, or because the T-UCR
and host gene expressions correlate for some other reasons.
Interestingly, many of the T-UCRs are located in cancer-related
regions and fragile sites, and their expression is frequently altered
in human cancer (Amos et al., 2017; Fabris and Calin, 2017;
Terracciano et al., 2017).
Breast cancer is the most common cancer in women
worldwide and the leading cause of female cancer deaths (Torre
et al., 2015). Breast cancer risk has a strong hereditary aspect,
especially genes encoding tumor suppressors, which play a role
in DNA damage response and repair pathways, are mutated
in hereditary breast cancer (Goldgar et al., 1994; Lichtenstein
et al., 2000; Collaborative Group on Hormonal Factors in
Breast Cancer, 2001; Nielsen et al., 2016). BRCA1 and BRCA2
genes carry pathogenic variants of high-penetrance that cover
approximately 20% of the familial relative risk (Mavaddat et al.,
2015). Other variants, the majority of them with moderate or low
penetrance, have been found to cover little over 20%, putting the
altogether familial relative risk coverage to approximately 44%
(Michailidou et al., 2017). Up to the present, nearly 200 low-
penetrance susceptibility loci have been identified. While high-
and moderate-penetrance variants are often in protein coding
regions, low-penetrance variants are typically located in non-
coding regions (Ghoussaini et al., 2013; Michailidou et al., 2017;
Milne et al., 2017).
Recently, several studies have shown a link between genetic
variants in lncRNA genes and breast cancer risk. Cui et al.
(2018) found a SNP 2 kb upstream of H19 transcription start site
that was associated with breast cancer risk in estrogen receptor
(ER)-positive patients in the Chinese population. Wu et al.
(2018) studied risk associations among 22977 cases and 105974
controls of European ancestry and found several novel risk-loci
that harbored lncRNA genes. Three of these lncRNAs, and four
altogether (ANRIL, H19, PVT1, and IGF2-AS), were reported to
have disease association based on SNP-association either with
breast cancer or prostate cancer risk or survival (Eeles et al., 2009;
Turnbull et al., 2010; Meyer et al., 2011; Riaz et al., 2012). In
addition, several lncRNAs have been found to be differentially
expressed in various breast cancer subtypes (Mathias et al., 2019).
While the precise functionality of lncRNAs in breast cancer
remains to be elucidated, they play a role in the regulation of
intracellular and intercellular signaling (Klinge, 2018).
The Breast Cancer Association Consortium (BCAC) is an
international multidisciplinary consortium with a focus on
inherited risk of breast cancer1. Their aim is to combine data from
many studies to identify genes related to breast cancer risk and,
with the world’s largest collection of breast cancer case samples
and controls, provide a powerful assessment of risk associated
with the studied genes. BCAC has the largest genomic breast
cancer dataset worldwide. Several papers describe in detail BCAC
and genotyping projects using the BCAC dataset (Michailidou
et al., 2013, 2015, 2017).
In this study, we look into the breast cancer risk association
of SNPs on lncRNAs expressed in mammary tissue or associated
with known breast cancer risk genes, as well as SNPs located
at the T-UCRs. We carried this out by analyzing the Breast
Cancer Association Consortium’s (BCAC) GWAS, OncoArray,
and iCOGs SNP array summary statistics to find SNPs in or
near lncRNAs or T-UCRs that associate with breast cancer risk.
The loci with GWAS-significant results have been published
recently (Michailidou et al., 2017; Milne et al., 2017), and in
this study we concentrate on the lncRNA and T-UCR related
SNPs with p < 10−5 to uncover other candidate lncRNA loci
for further analysis. The functionality of the SNPs of interest
was studied with integrated expression quantitative trait and
in silico prediction of GWAS targets (INQUISIT; Michailidou
et al., 2017) and eQTL analysis. We found putative breast cancer
risk variants associated with the expression of lncRNA GA-
binding protein transcription factor beta subunit 1 antisense
RNA 1 (GABPB1-AS1), cytoplasmic polyadenylation element
binging protein 4 (CPEB4) associated with uc.184, and TIA 1
cytotoxic granule associated RNA binding protein like 1 (TIAL1)
associated with uc.313.
MATERIALS AND METHODS
The work flow of the study is presented in Figure 1.
Study Population
The analyses were based on summary results of the Breast Cancer
Association Consortium (BCAC). The collaborative dataset of
the BCAC contained 122970 female breast cancer case samples
and 105974 controls of European ethnicity. Of these, 61282
cases and 45494 controls were genotyped using OncoArray
(Amos et al., 2017), and 46785 cases and 42892 controls
1http://bcac.ccge.medschl.cam.ac.uk/
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FIGURE 1 | Workflow chart of the study.
using iCOGs (Michailidou et al., 2013), while 14910 cases
and 17588 controls came from 11 other breast cancer GWAS
experiments (Michailidou et al., 2015). All participating studies
were approved by their appropriate institutional ethics review
board and all subjects provided informed consent. All research
was performed in accordance with the relevant guidelines
and regulations.
Selection of lncRNA Regions for the
Study
We selected 565 regions of lncRNAs and T-UCRs.
Following a comprehensive search for relevant lncRNAs
we selected altogether 84 lncRNA regions with reported
polymorphisms based on multiple criteria including tissue
specific expression, positive expression correlation with high
and moderate penetrance genes, and known disease associations
(Supplementary Table S1). 46 lncRNAs had expression above
five tags per million (Gibb et al., 2011) in breast tumor tissue.
Ten of these, and 25 other lncRNAs, showed positive expression
correlation with high and moderate penetrance genes (ten
with BRCA1, three with BRCA2, two with ATM, one with
CDH1, three with CHEK2, two with PALB2, thirteen with
RAD51C, and one with TP53). Several lncRNAs showed positive
correlation with multiple of these genes, but here only the
strongest correlations are listed (Supplementary Table S1).
For the correlation analysis, we used expression data from
GENCODE. The expression data as normalized RPKM (reads
per kilobase per million mapped reads) values was retrieved
from GENCODE database v7 (Derrien et al., 2012). Twenty-two
lncRNAs had a reported disease association defined either by
higher expression in a tumor tissue compared to a normal
tissue or by chromosomal aberrations in lncRNA regions in
samples from breast, ovarian or prostate cancer (data retrieved
from Long Non-coding RNA Database (Amaral et al., 2011),
LncRNADisease database (Chen et al., 2013) and literature
in March 2013) (Supplementary Table S2). Three of these
lncRNAs, and four altogether (ANRIL, H19, PVT1, and IGF2-
AS) were reported to have disease association based on SNP
association either with breast cancer or prostate cancer risk or
survival (Eeles et al., 2009; Turnbull et al., 2010; Meyer et al.,
2011; Riaz et al., 2012). For these 84 lncRNAs we included SNPs
located in exons and 50 kb flanking regions, 5′UTRs, and 150
nucleotides upstream from a transcription starting site. The SNPs
in the 84 lncRNA regions were genotyped on the OncoArray
genotyping chip (Amos et al., 2017). In addition, we selected
44 T-UCR regions that were either highly expressed in normal
breast tissue and/or had a known enhancer activity and/or were
located at cancer-associated genomic regions (Calin et al., 2007;
Scaruffi, 2011) (Supplementary Table S3). SNPs in these T-UCR
loci, including 50 bp extended region on both sides, with 1000
genomes European MAF ≥ 0.0013 were selected for genotyping
on the OncoArray.
Here, we have included in the analysis all the genotyped SNPs
in the 84 lncRNA regions and 44 T-UCR regions, and extended
our study to also include the remaining T-UCR regions resulting
in an extensive explorative study of all the 481 T-UCR regions in
the genome (Bejerano et al., 2004). While Bejerano et al. (2004)
reported no evidence that 256 of these 481 ultraconserved regions
were transcribed, Calin et al. (2007) found that 93% of these
regions were transcribed in at least one normal human tissue.
Thus we decided to include all ultraconserved regions in this
study alongside the other lncRNAs, as well as to refer to them
as T-UCRs.
The regions of interest that were used to gather SNPs from
the BCAC results database were defined as the above mentioned
565 lncRNA or T-UCR of interest, and 50 kb flanking it in
both directions.
Genotyping
OncoArray contains approximately 533000 markers, while
iCOGS holds 211000 (18, 19). Their genotyping and the
genotyping of the eleven GWAS in the BCAC has been previously
described in detail (Michailidou et al., 2013, 2015, 2017). All
samples were imputed using the version 3 (October 2014)
release of the 1000 Genomes Project dataset as the reference
panel. For iCOGS, OncoArray, and nine of the eleven GWAS,
the imputation was carried out with a 2-stage approach using
SHAPEIT2 for phasing and IMPUTE v2 for imputation; the two
remaining GWAS were imputed separately using MaCH and
Minimac (Howie et al., 2009, 2012; Li et al., 2010; O’Connell et al.,
2014). The details of the imputation process have been described
previously (Michailidou et al., 2017). Summary statistics used in
the study were obtained through BCAC. In this study, we looked
at associations in 565 specific regions, and used a p-value of
p < 10−5 as the limit of interrogation.
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Target Gene Prediction
The functionality of the putative breast cancer risk variants
was assessed by annotating each variant with publicly available
genomic data from breast cells and by using a heuristic
scoring system (Integrated Expression Quantitative trait and
in silico prediction of GWAS targets, INQUISIT) that combines
genomic data from multiple sources, including chromatin
interactions, computational enhancer–promoter correlations,
transcription factor binding chromatin immunoprecipitation
followed by sequencing, gene expression and topologically
associated domain boundaries, and which is described in
detail by Michailidou et al. (2017). For this study, the target
gene predictions were made from annotation in MCF7 and
HMEC cells, and the prediction methods were chromatin
interaction analysis by paired-end tag sequencing (ChIA-
PET), integrated methods for predicting enhancer targets
(IM-PET) and analysis of super-enhancers as defined by
Hnisz et al. (2013).
Expression Quantitative Trait Loci (eQTL)
Analysis
The Genotype-Tissue Expression (GTEx) project’s breast tissue
eQTL results (version 7) were used to detect SNP associations
with gene expression. The dataset included 251 normal breast
tissue samples. The data used for the analyses in this study
were downloaded from the GTEx Portal2 on February 13th,
2018 (version 7).
In addition, an eQTL analysis of the Molecular Taxonomy
of Breast Cancer International Consortium (METABRIC,
Curtis et al., 2012) dataset was carried out. The raw genotype
data (Affymetrix SNP 6.0 platform) and normalized mRNA
expression data (Illumina HT-12 v3 platform) extracted from
matched DNA and RNA specimens of tumorous breast tissue
were downloaded from the European Genome-phenome
Archive3. The genotype data was processed with Affymetrix
Genotyping Console Software following the practices of
the Affymetrix SNP 6.0 analysis workflow. The workflow
including a quality control step has been previously described
(Jamshidi et al., 2015; Khan et al., 2015). After the quality
control, the analysis contained 1328 samples with both
genotype and expression data. The analysis was carried out
using R-package Matrix eQTL with linear regression model
(Shabalin, 2012).
The recently published database ncRNA eQTL was queried to
validate GABPB1-AS1 eQTL results4 (Li et al., 2019).
Statistical Analysis
The BCAC summary results included a meta-analysis of
OncoArray, iCOGS and 11 GWAS analyses, as well as effect size
and standard error and p-value for these analyses for all variants.
The meta-analysis has been described in detail in Michailidou





cut-off of 0.5 was used to evaluate the importance of the findings.
FDR was calculated with the Benjamini–Hochberg procedure for
all SNPs in the regions of interest using the R 3.5.2 environment
(R Core Team, 2013)6.
Statistical analysis of INQUISIT is described in
detail in Michailidou et al. (2017).
For the eQTL analysis results, a cut-off of nominal p = 0.05
was used. The eQTL data available at the GTEx Portal included
p-values, normalized size effect (NES) and standard error to
NES. The R-package Matrix eQTL used to carry out METABRIC
eQTL analysis also provided FDR p-values. Those were viewed
as additional information for the discussion. ncRNA eQTL
statistical information included beta, r, and p-values.
Online Bioinformatics Tools
Linkage disequilibrium between SNPs was checked using Broad
Institutes SNP annotation and proxy search (SNAP v2.2; Johnson
et al., 2008) and LDlink (v3.7; Machiela and Chanock, 2015).
Promoter/enhancer loci were browsed using GeneHancer in
GeneCards (7, version 4.7, accessed 4.5.2018, Fishilevich et al.,
2017). Gene and SNP positions were checked using the UCSC
Genome Browser (8, Kent et al., 2002) and Ensembl genome
browser 92 (9, Zerbino et al., 2018).
RESULTS
In this study, we looked into the breast cancer risk association
of SNPs in the regions of breast cancer-relevant lncRNAs and
of T-UCRs around the genome in a large cohort of European
breast cancer patients. We selected altogether 565 lncRNA
regions that included 84 lncRNAs with reported polymorphisms
based on multiple criteria, including tissue specific expression,
co-expression with high and moderate penetrance genes, and
known disease associations, and 481 ultraconserved regions. 153
ultraconserved regions including the 44 T-UCRs selected for the
OncoArray were either highly expressed in normal breast tissue
and/or had a known enhancer activity and/or were located at
cancer-associated genomic regions while no such information
was available for the rest of the ultraconserved regions. The
regions of interest were defined as the transcribed lncRNA/T-
UCR and 50 kb up- and downstream genomic sequence. For
the sake of brevity and clarity, we numbered the lncRNA
regions and refer to those numbers in this article instead
of the subject lncRNA of the region. The nomenclature for
the ultraconserved regions came from the article by Bejerano
et al. (2004). All regions, genes and the rationales for selecting
them for this study can be found in Supplementary Table
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SNPs in Seven lncRNAs and Eight
T-UCRs Associated With Breast Cancer
Risk
We used BCAC summary statistics on risk results from meta-
analysis of OncoArray, iCOGS and 11 separate genome-wide
association studies (GWAS). The regions of interest included
5401 genotyped and 349112 imputed SNPs. Results with genome-
wide significance level (p < 5 × 10−8) for five of the lncRNA
regions and 18 of the T-UCR regions have previously been
published by the BCAC and are listed in Supplementary
Table S4. These regions are undergoing further fine mapping
studies by the BCAC. Here, a p-value of <10−5 and MAF <0.45
was used as the limit of interrogation, resulting in seven lncRNA
regions and eight T-UCRs containing three genotyped and 248
imputed SNPs not previously reported by the BCAC (Tables 1, 2).
FDR was calculated for all the SNPs in the regions of interest
to evaluate the importance of the findings (Supplementary
Table S5). None of the SNPs in the T-UCR regions were directly
in the T-UCRs themselves, but in the regions flanking them.
This is expected due to the nature of ultraconservation, but
makes it difficult to analyze the relationship between the SNP and
the T-UCR.
In addition to the results from the meta-analysis of breast
cancer overall, we interrogated the meta-analysis results from ER-
negative and ER-positive patient subgroups separately (Table 3).
Fourteen SNPs (all imputed) were shared between the overall and
ER-negative analyses, all located in the uc.147 region, and 5 SNPs
had p< 10−5 in the ER-negative analysis only (all imputed). Nine
SNPs were shared between the overall and ER-positive analyses
(all imputed) and no SNP gave a p-value under the threshold in
ER-positive analysis only. None of the SNPs were shared by all
three subgroup analyses.
Integrated Expression Quantitative Trait
and in silico Prediction of GWAS Targets
(INQUISIT) Predicts Target Genes for 60
SNPs in Two lncRNAs and Four T-UCRs
A heuristic scoring system, INQUISIT (Michailidou et al., 2017),
was used to calculate the potential target genes for the 251 SNPs
that were associated with breast cancer risk in BCAC analysis
(Supplementary Table S6).
For 60 of the 251 SNPs, INQUISIT predicted one or more
target genes (Supplementary Table S7). There were 12 genes
predicted as targets altogether and each gene had 1-17 SNPs
predicting it. The SNPs resided on two lncRNAs regions and
on four T-UCRs; the number of SNPs per region ranged from
1-22. The predominant method of prediction was chromatin
interaction analysis by paired-end tag sequencing (ChIA-PET) in
MCF7. All these SNPs had association (p < 10−5) with overall
breast cancer, with FDR <0.005. Four SNPs in uc.313 were also
associated with ER-positive breast cancer. It is to be noted that
MCF7 is a breast cancer cell line which may cause alteration in its
cellular processes and may affect these results.
Overall, the INQUISIT-predicted target genes of the SNPs
were not the lncRNA or T-UCR of the SNPs region, but mostly
protein-coding genes. The only exception to this was GABPB1-
AS1, the subject of the lncRNA-75 region and targeted by three
lncRNA-75 SNPs in INQUISIT predictions. Three T-UCRs were
located within the gene that the SNPs in their regions targeted by
INQUISIT: uc.147 in the intron of LRBA, uc.184 in the 3′UTR of
CPEB4 and uc.313 in the intron of TIAL1.
We searched for genes that, in addition to being INQUISIT
target genes, show eQTL associations as well (see below).
There were three such genes in our data: GABPB1-AS1 (GTEx
eQTL analysis), CPEB4 and TIAL1 (METABRIC eQTL analysis)
(Table 4). Only in a few cases, the SNP targeting a gene in
INQUISIT predictions was the same SNP that associates to
the gene in eQTL (Table 5). However, the majority of these
SNPs are linked.
Three SNPs targeted GABPB1-AS1 of lncRNA-75 region
(rs1806845, rs71124350, and rs28489579) (Table 6). All three
clustered together approximately 31 kb downstream of the
lncRNAs. These SNPs also have additional predicted targets,
rs1806845 and rs71124350 target also SLC27A2 and GABPB1
and rs28489579 targets GABPB1 as well. However, none of
these other predicted targets show association with p < 0.05 in
the eQTL analyses.
CPEB4 was the predicted target of seventeen SNPs in the
uc.184 region (Table 7). The majority of the SNPs as well as
uc.184 itself are located in the 3′UTR of the CPEB4. None
of the SNPS overlap with uc.184. Two SNPs targeting CPEB4
also had other predicted targets, C5orf47 (rs17695092) and
NGS2 (rs55946741).
TIAL1 was targeted by ten SNPs (Table 8). The target T-UCR,
uc.313, overlaps none of the SNPs. Three SNPs also target RGS10
(rs2917941, rs3009877, rs75611822).
Two SNPs Targeting GABPB1-AS1 in
INQUISIT Also Associate With It in eQTL
Analysis of GTEx Dataset
GTEx eQTL association in normal mammary tissue with the
limit of p < 0.05 was found for 171 of the 251 SNPs in this
study (Supplementary Table S8). All in all, the SNPs had 318
associations with 22 genes. The SNPs were found on seven
lncRNA and five T-UCR regions (Supplementary Table S9).
Each SNP showed association to 1–4 genes and each gene to
1–48 SNPs. Only one gene, GABPB1-AS1, which was targeted
in INQUISIT predictions, also had SNP association in GTEx
analysis. GABPB1-AS1 was also the only SNP associated gene that
was also the target of a region of interest, lncRNA-75.
GABPB1-AS1 expression associated with 18 SNPs in lncRNA-
75 with p-values ranging from 2.45 × 10−7 to 4.47 × 10−14, and
FDR corrected p-values all below 0.05 (Table 6). Curiously, all 36
associations in GTEx data with FDR corrected p < 0.05 involved
SNPs located in lncRNA-75, and besides GABPB1-AS1, included
only lincRNA AC022087.1 which lies downstream of GABPB1-
AS1 in reverse orientation. Two SNPs of the 18 that associate with
GBPB1-AS1 in GTEx also target GABPB1-AS1 in the INQUISIT
analysis: rs71124350 (p = 2.7 × 10−7, normalized effect size
[NES] =−0.43) and rs28489579 (p = 1.6× 10−13, NES =−0.52).
The two SNPs are linked with r2 = 0.8996. All SNPs that show






















TABLE 1 | All lncRNA regions where SNPs with p < 10−5 were found.
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TABLE 2 | All ultraconserved regions where SNPs with p < 10−5 were found.
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association with GABPB1-AS1 expression are downstream of the
gene starting from approximately 4.7kb. Rs71124350 lies 31kb
and rs28489579 36kb from the gene.
CPEB4 and TIAL1 Associate With SNPs
Targeting Them in INQUISIT in eQTL
Analysis of METABRIC Dataset
Of the 251 SNPs in this study, 20 had eQTL associations with the
limit p < 0.05 in METABRIC (Supplementary Table S10). These
SNPs were spread on three lncRNA regions and five T-UCRs
(Supplementary Table S9). Even though the vast majority of the
found associations were in cis, the specific lncRNAs or T-UCRs of
the regions of interest were not associated with any of the SNPs.
Altogether, the SNPs had 10322 associations ranging from 352
to 1151 associations per SNP. These associations contain 5858
genomic elements, including genes, pseudogenes, and expressed
sequence tags. Each genetic element was associated with 1-17
SNPs. We focused on SNP and region associations with genes that
were also INQUISIT-predicted target genes. There were two such
genes, CPEB4 and TIAL1.
Two SNPs, rs17695092 and rs1564823 in region uc.184,
associated strongly in cis with CPEB4, p = 7.33 × 10−61 (after
FDR correction 3.76 × 10−55) and p = 3.66 × 10−64 (after
FDR correction 3.75 × 10−58) with beta coefficients of −0.317
and 0.324, respectively (Table 7). These SNPs have the lowest
p-values of the METABRIC analysis and they are in strong linkage
disequilibrium (r2 = 1.000). Both rs17695092 and rs1564823
as well as the T-UCR uc.184 are located within CPEB4 gene:
rs17695092 lies in the intron 2, while rs1564823 and uc.184 are
situated in the 3′UTR of the gene.
Three SNPS, rs4752331, rs3009879, and rs12569630 in uc.313,
associated in cis with TIAL1 in METABRIC (Table 8). Only
rs3009879 was predicted to target TIAL1 by INQUISIT. The
three SNPs are linked as r2 between rs3009879 and rs4752331
is 0.681, and between rs3009879 and rs12569630 r2 = 0.967.
Rs3009879 is intronic, located in the TIAL1, while rs4752331 and
rs12569630 are located 7.3 kb downstream and 6.1 kb upstream
of the TIAL1, respectively. However, while the p-values range
from 0.0013 to 0.0078, none survives FDR correction (all FDR
corrected are p-values >0.9). The beta coefficient for rs4752331
and rs12569630 variants is 0.04, and for rs3009879 – 0.04.
ncRNA eQTL Database Validates
GABPB1-AS1 eQTL Association
To validate the GABPB1-AS1 results from the GTEx eQTL
analysis, we looked for other eQTL resources. Non-coding RNA
eQTL database ncRNA eQTL was queried with the GABPB1-
AS1 GTEx eQTL results. The data base did not include the SNPs
rs71124350 and rs28489579. However, SNPs in strong linkage
disequilibrium with these SNPs of interest (r2 = 0.822 and 0.883,
respectively) were found in the ncRNA eQTL database, and their
results support the GTEx eQTL results: SNP rs35831049 linked
to the SNP of interest rs71124350 (r2 = 0.822) was associated with
GABPB1-AS1 with effect r =−0.35 (rs71124350 normalized effect
size [NES] =−0.43) and p = 9.29e-32, and SNP rs34565064 linked
to rs28489579 (r2 = 0.883) was associated with GABPB1-AS1 with
effect r =−0.35 (rs28489579 NES =−0.52 and p = 5.45e-32).
DISCUSSION
In this study, we looked into the connection between lncRNAs
and T-UCRs and breast cancer risk. The connection was
investigated by identifying putative breast cancer risk SNPs in
BCAC data located in or near lncRNAs and T-UCRs, assessing
the SNPs’ functional effects using heuristic scoring method
INQUISIT that predicts target genes for risk SNPs by combining
genomic information from multiple sources, and performing
eQTL analysis. These analysis methods are especially suitable
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TABLE 3 | Distribution of SNPs with p < 10−5 to regions. BC, breast cancer. MA, meta-analysis.
Regions Novel region SNPs Genotyped/imputed SNPS in MA of overall BC SNPs in MA of ER- SNPs in MA of ER+
lncRNA-2 No 125 23/102 125 0 110
lncRNA-17 Yes 2 0/2 2 0 0
lncRNA-26 Yes 20 0/20 20 0 0
lncRNA-43 No 129 9/120 114 0 107
lncRNA-45 Yes 1 0/1 1 0 0
lncRNA-49 Yes 1 0/1 0 1 0
lncRNA-69 No 234 122/112 189 70 116
lncRNA-75 Yes 20 3/17 20 0 0
lncRNA-82 Yes 1 0/1 1 0 1
lncRNA-92 No 34 15/19 32 0 32
lncRNA-98 No 16 11/5 13 0 16
lncRNA-103 Yes 9 0/9 9 0 0
uc.1 No 180 0/180 180 179 52
uc.2 No 2 0/2 2 1 0
uc.2/3 No 2 0/2 2 0 0
uc.2/3/4 No 9 0/9 7 2 0
uc.22/23 No 1 0/1 1 0 0
uc.23/24 No 1 0/1 1 0 0
uc.24 No 2 0/2 2 0 0
uc.24/25 No 2 0/2 2 0 0
uc.25 No 7 0/7 7 0 0
uc.29 No 11 0/11 1 0 11
uc.61 Yes 16 0/16 16 0 0
uc.98/99 No 11 0/11 8 0 11
uc.147 Yes 32 0/32 29 17 0
uc.148/149 Yes 1 0/1 0 1 0
uc.152 No 2 0/2 1 0 2
uc.162 No 33 5/28 33 15 0
uc.168 No 15 2/13 15 0 0
uc.175 No 85 0/85 85 23 79
uc.184 Yes 57 0/57 57 0 0
uc.201 Yes 1 0/1 1 0 0
uc.245 No 57 0/57 52 0 57
uc.250 Yes 43 0/43 43 0 0
uc.313 Yes 46 0/46 46 0 8
uc.386 Yes 1 0/1 1 0 0
uc.401 No 60 0/60 5 15 55
for gaining insight into the role of SNPs located in the areas
flanking the lncRNAs and T-UCRs and not directly affecting their
sequence. All the SNPS found in this study to be associated with
breast cancer were flanking SNPSs.
Of the 1303 breast cancer risk associated SNPs in 12 lncRNA-
and 26 T-UCR loci in the study, 251 were in loci not previously
reported by BCAC (7 lncRNA and 8 T-UCR), and for 60 of these
in two lncRNA regions and 4 T-UCR, INQUISIT predicted a
target gene. For three of these genes, also an eQTL association
was found in METABRIC or GTEx eQTL analysis (Table 4).
INQUISIT analysis predicted GABPB1-AS1 as the target for
two SNPs, rs71124350, and rs28489579, and the same SNP-
gene association was seen in GTEx eQTL analysis of normal
mammary tissue (Table 5). Results of a query to the ncRNA
eQTL database support the eQTL association of GABPB1-AS1,
and SNPS rs71124350 and rs28489579, although the database
did not include these specific SNPs but others in strong linkage
disequilibrium with them. In eQTL analysis of METABRIC breast
cancer tissue data, CPEB4 was found to be associated with SNP
rs17695092, and the same SNP had CPEB4 also as an INQUISIT
target gene. Similarly, rs3008979 and TIAL1 had METABRIC
association and were a SNP-predicted target gene pair, although
the p-values for TIAL1 eQTL association did not survive FDR
correction. In addition to these loci with functional data available,
other candidate regions were identified containing SNPs with the
defined p-value and highly significant FDR for breast cancer risk
association (Supplementary Table S5).
The two GABPB1-AS1 targeting SNPs, rs71124350 and
rs28489579, are linked (r2 = 0.8996) and located near each
other. According to a database of human enhancers, between
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TABLE 4 | Genes that are both INQUISIT predicted target genes and have
eQTL associations.






GABPB1-AS1 lncRNA-75 3 18
CPEB4 uc.184 17 2
TIAL1 uc.313 10 3
the two SNPs lies a GABPB1-AS1 enhancer site (GeneHancer ID
GH15I050390). This site is not a direct enhancer of GABPB1,
and concordantly rs71124350 and rs28489579 do not have an
eQTL association with GABPB1. As the minor alleles of both
rs71124350 and rs28489579 are also associated with a small
decrease in breast cancer risk (Table 6), these findings suggest
that the decrease in GABPB1-AS1 expression associates with
decreased breast cancer risk.
GABPB1-AS1 is an lncRNA located in 15q21.2, partially
overlapping GABPB1 read from the opposite stand. There are
reports of non-coding RNAs and the protein-coding genes they
overlap displaying coordinated expression and function, which
can be synergistic or antagonistic (39, 40). Commonly, the role of
antisense RNAs is to bind the sense-oriented mRNA, and thus
block its translation. There are no reports on how GABPB1-
AS1 affects the expression of GABPB1, but they share common
promotor/enhancer loci according to GeneHancer: of the 18
promoter/enhancer regions associated with GABPB1-AS1, nine
were also associated with GABPB1. GABPB1 is a transcription
factor and an activator of BRCA1 expression (Atlas et al., 2000). If
we assume the antisense – sense relationship between GABPB1-
AS1 and GABPB1 to be an antagonistic one, it would suggest
that GABPB1-AS1 downregulates GABPB1, which in turn would
lead to repression of BRCA1. This would be consistent with the
results of this study: SNPs associated with reduced GABPB1-
AS1 are also associated with reduced breast cancer risk, and this
effect could be the result of the increased GABPB1 expression
leading to increased BRCA1 expression. However, GABPB1-
AS1 was selected for this study based on positive correlation
between GABPB1-AS1 and BRCA1 expression. It is possible
that the regulatory relationships are more complex than seen
here, and the correlation between overall expression levels may
not imply causation. Further research is required to clarify the
functional interactions between these genes, as at this point,
we can only speculate on the functional role of GABPB1-AS1in
breast cancer predisposition.
For the other two discovered loci, the regions were included
as T-UCR harboring loci but the discovered risk SNPs were
associated in eQTL and INQUISIT analyses with protein coding
genes: rs17695092 in uc.184 with CPEB4, and rs3009879 in
uc.313 with TIAL1. Uc.184 and uc.313 are located in CPEB4 and
TIAL1, respectively. However, T-UCR expression is challenging
to study, as they do not appear in expression databases. This
is at least partly due to the difficulty in separating intragenic
T-UCR expression from the expression of its host gene. Mestdagh
et al. (2010) found uc.184 expression to be inseparable from
CPEB4 expression, while uc.313 expression was found to be
independent of TIAL1 expression. However, Mestdagh et al.
looked at the expressions in neuroblastoma and the situation
in breast tissue is unknown. Nevertheless, uc.187 and uc.313
are likely to play a substantial role in the correct function of
their host genes, as such conservation is unlikely to remain
intact by chance. Uc.184 and uc.313 are located in the 3′UTR
and in an intron, respectively, and alterations in these regions
often have a major regulatory effect on the function of a gene
(Li and Yuan, 2017; Park et al., 2018). The fidelity of these
regions may be essential to the correct function of the CPEB4
and TIAL1.
The 3′UTR of the CPEB4 contains 13 of the 17 SNPs that target
CPEB4 in INQUISIT prediction and one of the two SNPs with
CPEB4 expression association in METABRIC. T-UCR uc.184 is
also located there. CPEB4 is a member of a CPEB family of
proteins that bind RNA in a sequence-specific manner, contain
two RNA recognition motifs, two zinc fingers and a regulatory
N-terminal region (Hake and Richter, 1994; Fernandez-Miranda
and Mendez, 2012). CPEBs regulate translation by controlling
the polyadenylation of their target genes (Mendez and Richter,
2001; Richter, 2007). There are no previous reports of CPEB4
affecting breast cancer risk, but overexpression of CPEB4 is
reported in breast cancer, and the overall survival of patients
with high expression of CPEB4 is shorter (Sun et al., 2015; Lu
et al., 2017). Ectopic CPEB4 expression has been suggested to
promote EMT, migration and invasion of breast cancer cells,
while silencing the expression of CPEB4 reduces these events
(Lu et al., 2017). Our results imply that CPEB4 may also play
a role in the breast cancer development as the intronic SNP
rs17695092 associates with both reduced CPEB4 expression, and
reduced breast cancer risk (Table 7). It is to be noted that the
METABRIC dataset consists of breast cancer samples, and the
effect is not seen in the eQTL analysis in the GTEx dataset of
normal mammary tissue samples. The difference could be due to
difference in statistical power, as the METABRIC dataset includes
over 1300 breast cancer samples, whereas the GTEx dataset is 251
normal breast cancer tissues. It is notable that the cell line used
in the CHiA-PET analysis from which the INQUISIT results for
rs17695092 were gathered was MCF7, which is a breast cancer cell
TABLE 5 | SNPs that both have INQUISIT predicted target genes and have eQTL associations.
Variant Gene Region MAF OR (95%CI) BCAC p BCAC p eQTL eQTL
rs71124350 GABPB1-AS1 lncRNA-75 0.3354 0.97 (0.957–0.983) 0.00000784 2.41918E-07 GTEx
rs28489579 GABPB1-AS1 lncRNA-75 0.3444 0.97 (0.957–0.983) 0.000005277 1.56507E-13 GTEx
rs17695092 CPEB4 uc.184 0.3149 0.969 (0.956–0.982) 0.000002644 7.33215E-61 METABRIC
rs3009879 TIAL1 uc.313 0.4089 1.03 (1.017–1.043) 0.000003064 0.001347099 METABRIC






















TABLE 6 | Variants with GABPB1-AS1 as INQUISIT predicted target gene and/or GTEx eQTL association.
Variant Chr Position Position in
relation to
GABPB1-AS1
Alleles Breast cancer risk (BCAC) (meta-analysis, all samples) INQUISIT? GTEx
OR (95 %CI) SE p FDR NES NES SE p
rs606118 15 50655171 upstream C/T 0.971 (0.9588–0.9840) 0.0066 0.000009757 0.00228261707542373 No Yes 0.53 0.06 5.2 × 10−14
rs11634585 15 50656449 upstream G/A 0.971 (0.9591–0.9839) 0.0065 0.000009465 0.00223705437071918 No Yes 0.51 0.06 4.9 × 10−14
rs1056682 15 50660201 upstream A/G 0.971 (0.9588–0.9840) 0.0066 0.000009377 0.0022257837394669 No Yes −0.53 0.06 5.7 × 10−14
rs17431150 15 50663582 upstream G/A 0.971 (0.9587–0.9839) 0.0066 0.000008556 0.00208100765814978 No Yes −0.53 0.06 4.5 × 10−14
rs17431171 15 50663621 upstream G/A 0.971 (0.9587–0.9839) 0.0066 0.00000855 0.00208100765814978 No Yes −0.53 0.06 5.2 × 10−14
rs34565064 15 50663903 upstream G/A 0.971 (0.9591–0.9839) 0.0065 0.000009597 0.00226098220392492 No Yes −0.51 0.06 4.9 × 10−14
rs720599 15 50664515 upstream C/A 0.971 (0.9586–0.9838) 0.0066 0.000007992 0.00196285368683274 No Yes −0.53 0.06 5.2 × 10−14
rs12905736 15 50667009 upstream G/A 0.968 (0.9548–0.9822) 0.0072 0.000008952 0.00215079396344648 No Yes −0.54 0.07 4.2 × 10−12
rs55948407 15 50668901 upstream G/A 0.970 (0.9575–0.9826) 0.0066 0.000004237 0.0011675312003988 No Yes −0.51 0.07 4.2 × 10−13
rs55941574 15 50668966 upstream C/T 0.970 (0.9569–0.9824) 0.0067 0.000004257 0.00117049267828685 No Yes −0.5 0.07 1.5 × 10−11
rs35628775 15 50671563 upstream T/C 0.970 (0.9579–0.9830) 0.0066 0.00000573 0.00149755046168401 No Yes −0.52 0.07 1.6 × 10−13
rs35541701 15 50673001 upstream G/A 0.970 (0.9569–0.9824) 0.0067 0.000004296 0.00117886766600398 No Yes −0.51 0.07 8.2 × 10−13
rs34174311 15 50673281 upstream T/C 0.971 (0.9582–0.9833) 0.0066 0.000006915 0.00174424701186131 No Yes −0.52 0.07 1.6 × 10−13
rs4775880 15 50675818 upstream A/G 0.970 (0.9576–0.9831) 0.0067 0.000005656 0.00148561217126546 No Yes 0.46 0.07 5.9 × 10−11
rs28817272 15 50677213 upstream G/A 0.970 (0.9575–0.9830) 0.0067 0.000005417 0.00143237621551724 No Yes −0.46 0.07 2.6 × 10−11
rs1806845 15 50681906 upstream G/T 0.971 (0.9580–0.9835) 0.0067 0.000009599 0.00226098220392492 Yes No
rs71124350 15 50682294 upstream T/TA 0.970 (0.9572–0.9831) 0.0068 0.00000784 0.00193412589812332 Yes Yes −0.43 0.08 2.4 × 10−7
rs28489579 15 50686778 upstream G/C 0.970 (0.9574–0.9829) 0.0067 0.000005277 0.00140477607425265 Yes Yes −0.52 0.07 1.6 × 10−13
rs4774565 15 50694306 upstream A/G 0.968 (0.9546–0.9808) 0.0069 0.000002194 0.000674464429844098 No Yes −0.43 0.06 5.9 × 10−11







































TABLE 7 | Variants with CPEB4 as INQUISIT predicted target gene and/or METABRIC eQTL association.
Variant Chr Position Position in
relation to
CPEB4
Linkage Alleles Breast cancer risk (BCAC) (meta-analysis, all samples) INQUISIT? METABRIC
r2 OR (95 %CI) SE p FDR Beta p (FDR
corrected)
rs17695092 5 173337603 intron 2 1 T/G 0,969 (0,9563–0,9818) 0.0067 2.644E-06 0.0007848 Yes Yes −0.31702 3.75723E-55
3′UTR start 5 173385302
rs1564823 5 173383194 3′UTR 1 C/A 0,968 (0,9553–0,9807) 0.0067 1.062E-06 0.0003778 No Yes 0.32461 3.75057E-58
rs7736263 5 173339222 3′UTR 0.986 G/T 0,968 (0,9556–0,981) 0.0067 1.35E-06 0.0004578 Yes No
rs112299234 5 173339531 3′UTR 1 T/C 0,968 (0,9553–0,9807) 0.0067 1.038E-06 0.0003717 Yes No
rs72812804 5 173340496 3′UTR 1 T/G 0,968 (0,9557–0,9811) 0.0067 1.428E-06 0.0004738 Yes No
rs72812805 5 173344153 3′UTR 1 T/C 0,968 (0,9557–0,9811) 0.0067 1.436E-06 0.000474 Yes No
rs55946741 5 173345023 3′UTR 1 A/G 0,969 (0,9559–0,9813) 0.0067 1.667E-06 0.0005357 Yes No
rs10516107 5 173348156 3′UTR 1 G/A 0,968 (0,9557–0,9811) 0.0067 1.465E-06 0.0004795 Yes No
rs72812811 5 173350990 3′UTR 1 G/A 0,968 (0,9557–0,9811) 0.0067 1.465E-06 0.0004795 Yes No
rs17695555 5 173351081 3′UTR 1 C/T 0,968 (0,9557–0,9811) 0.0067 1.466E-06 0.0004795 Yes No
rs17763083 5 173351488 3′UTR 1 C/T 0,968 (0,9557–0,9811) 0.0067 1.463E-06 0.0004795 Yes No
rs747472 5 173353514 3′UTR 0.273 T/C 0,968 (0,9557–0,9811) 0.0067 1.419E-06 0.0004726 Yes No
rs17076726 5 173363889 3′UTR 0.995 C/T 1,03 (1,0172–1,0426) 0.0063 3.108E-06 0.000891 Yes No
rs56245789 5 173365310 3′UTR 1 T/C 0,968 (0,9553–0,9807) 0.0067 1.057E-06 0.0003765 Yes No




3′UTR stop 5 173387994
rs6890591 5 173392315 Upstream 0.672 T/A 0,972 (0,9598–0,9842) 0.0064 9.893E-06 0.0023027 Yes No
rs6869166 5 173392403 Upstream 0.68 A/G 0,972 (0,9597–0,9841) 0.0064 9.193E-06 0.0021953 Yes No
rs67623241 5 173392638 Upstream 0.674 C/G 0,971 (0,9593–0,9837) 0.0064 6.857E-06 0.0017337 Yes No







































TABLE 8 | Variants with TIAL1 as INQUISIT predicted target gene and/or METABRIC eQTL association.
Variant Chr Position Position in
relation to
TIAL1
Linkage Alleles Breast cancer risk (BCAC) (meta-analysis, all samples) INQUISIT? METABRIC
r2 OR (95%CI) SE p FDR Beta p
rs10886511 10 121307823 downstream 0.493 G/A 1,033 (1,0186–1,0485) 0.0074 7.84E-06 1.93E-03 Yes No
rs10787979 10 121307837 downstram 0.365 G/A 1,037 (1,0221–1,0522) 0.0074 7.71E-07 2.91E-04 Yes No
rs4752331 10 121323976 downstram 0.702 A/G 1,033 (1,0194–1,0465) 0.0067 1.22E-06 4.24E-04 No Yes −0.04 0.007772
rs2917941 10 121328421 downstram 0.716 A/T 1,034 (1,0204–1,0471) 0.0066 5.46E-07 2.13E-04 Yes No
rs3009877 10 121328495 downstram 0.716 G/A 1,034 (1,0205–1,0472) 0.0066 5.18E-07 2.03E-04 Yes No
rs75611822 10 121329179 downstram 0.407 ACT/A 1,035 (1,0196–1,05) 0.0075 5.06E-06 1.36E-03 Yes No
rs10712346 10 121332690 downstram 0.996 AC/A 1,03 (1,0174–1,0433) 0.0064 3.91E-06 1.09E-03 Yes No
rs72040146 10 121332870 downstram 0.996 TAA/T 1,031 (1,0177–1,0436) 0.0064 3.03E-06 8.73E-04 Yes No
TIAL1 stop 10 121332978




rs3816145 10 121347329 intron 2/3 0.409 T/C 1,033 (1,0184–1,0483) 0.0074 9.83E-06 2.29E-03 Yes No
rs146020828 10 121347839 intron 1/2 0.378 TTTTC/T 1,036 (1,0213–1,0514) 0.0074 1.45E-06 4.77E-04 Yes No
TIAL1 start 10 121356541
rs12569630 10 121362660 upstream 0.955 A/G 1,031 (1,018–1,0439) 0.0064 1.69E-06 5.42E-04 No Yes −0.04 0.002971


















fgene-11-00550 June 30, 2020 Time: 12:37 # 13
Suvanto et al. lncRNA SNPs in Breast Cancer
line. This requires further research, as does the role of the uc.184
in the 3′UTR of the CPEB4.
Uc.313 is located in the intron 5 or 6 of the TIAL1, depending
on the transcript (and in a single transcript, NM_001323964.1,
out of the eleven UCSC annotations of the RefSeq RNAs, it
partially overlaps exon six). Of the twelve SNPs that target
TIAL1 in INQUISIT prediction, or as METABRIC association,
the majority are located downstream of the gene, three are
in the TIAL1, all intronic, and one is located upstream of
the gene (Table 8). The SNP with TIAL1 as both INQUISIT
target and METABRIC association, rs3009879, is one of the
three intronic variants. Rs3009879 does not appear to overlap
any regulatory sequence elements (assessed by using Ensembl
genome browser 92 and GeneHancer in GeneCards), but as it
does target TIAL1 in INQUISIT, a connection discovered by
the CHiA-PET method, it suggests involvement in a chromatin
interaction. It is worth noting that in METABRIC eQTL analysis,
the significance of rs3009879 association withTIAL1 expression
was p = 0.0013, but it did not survive FDR correction. Thus,
it is also possible that the eQTL association of this variant
withTIAL1 is an artefact.
TIAL1 (also known as TIAR), is a ubiquitously expressed
RNA binding protein that contains three N-terminal RNA
recognition motifs and a C-terminal glutamine-rich prion-like
domain, which is found to aggregate during the formation
of cytoplasmic stress granules (Dember et al., 1996; Gilks
et al., 2004; Kim et al., 2013). TIAL1 is a negative regulator
of BRCA1: it is shown to block translation, and at least in
chronic myeloid leukemia cells, reduce the protein expression
of BRCA1 which leads to aneuploidy, spindle toxin resistance,
and genomic instability (Deutsch et al., 2003; Wolanin et al.,
2010; Podszywalow-Bartnicka et al., 2014). If TIAL1 has the
same effect on BRCA1 protein expression in breast cancer,
it is plausible that SNPs that increase TIAL1 expression also
increase breast cancer risk, as is the case with rs3009879
(Supplementary Table S9).
Previously, SNPs with genome-wide significant associations
(p < 5 × 10−8) with breast cancer risk have been reported in
several genomic regions containing lncRNAs (Michailidou et al.,
2017; Milne et al., 2017). In this study, we aimed to identify
additional candidate loci for further studies. We report here
putative breast cancer risk SNPs predicted to functionally target
GABPB1-AS1 lncRNA, and associating with its expression, as well
as SNPs in two genes, CPEB4 and TIAL1, hosting ultraconserved
regions, uc.184 and uc.313, respectively. Further research is
needed to validate these findings and candidate genes, and
elucidate the functional mechanisms involved. In addition, other
regions containing SNPs with the defined p-value and highly
significant FDR for breast cancer risk association, but currently
lacking the functional data, may warrant further studies.
DATA AVAILABILITY STATEMENT
The analyses were based on summary results of the Breast Cancer
Association Consortium (BCAC), available online at: http://bcac.
ccge.medschl.cam.ac.uk/.
ETHICS STATEMENT
All participating BCAC studies were approved by their
appropriate institutional ethics review boards for the initial
BCAC study. This study uses only publicly available BCAC-
summary data, no individual data.
AUTHOR CONTRIBUTIONS
SK and HN designed the study. MS and SK carried out the data
and eQTL analyses, wrote the main manuscript text and prepared
the figures and the tables. CB provided clinical expertise and
critically reviewed the manuscript. JB and GC-T provided the
INQUISIT analysis. All authors contributed to and approved the
final manuscript.
FUNDING
The Helsinki Study was funded by the Helsinki University
Hospital Research Funding, the Sigrid Jusélius Foundation,
and the Cancer Foundation Finland. GC-T and JB were
supported by the funding of the National Health and Medical
Research Council. BCAC is funded by Cancer Research
United Kingdom (C1287/A16563 and C1287/A10118), the
European Union’s Horizon 2020 Research and Innovation
Programme (grant numbers 634935 and 633784 for BRIDGES
and B-CAST, respectively), and by the European Community’s
Seventh Framework Programme under grant agreement number
223175 (grant number HEALTH-F2-2009-223175) (COGS).
The EU Horizon 2020 Research and Innovation Programme
funding source had no role in study design, data collection, data
analysis, data interpretation or writing of the report. Genotyping
of the OncoArray was funded by the NIH Grant U19 CA148065,
and Cancer United Kingdom Grant C1287/A16563, and the
PERSPECTIVE project supported by the Government of Canada
through Genome Canada and the Canadian Institutes of Health
Research (grant GPH-129344) and the Ministère de l’Économie,
Science et Innovation du Québec through Génome Québec
and the PSRSIIRI-701 grant, and the Quebec Breast Cancer
Foundation. Funding for the iCOGS infrastructure came from:
the European Community’s Seventh Framework Programme
under grant agreement n◦ 223175 (HEALTH-F2-2009-223175)
(COGS), Cancer Research United Kingdom (C1287/A10118,
C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384,
C5047/A15007, C5047/A10692, and C8197/A16565), the
National Institutes of Health (CA128978) and Post-Cancer
GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19
CA148112 – the GAME-ON initiative), the Department of
Defense (W81XWH-10-1-0341), the Canadian Institutes of
Health Research (CIHR) for the CIHR Team in Familial Risks of
Breast Cancer, and the Susan G. Komen Foundation for the Cure,
the Breast Cancer Research Foundation, and the Ovarian Cancer
Research Fund. The DRIVE Consortium was funded by U19
CA148065. Combining the GWAS data was supported in part
by the National Institutes of Health (NIH) Cancer Post-Cancer
Frontiers in Genetics | www.frontiersin.org 13 June 2020 | Volume 11 | Article 550
fgene-11-00550 June 30, 2020 Time: 12:37 # 14
Suvanto et al. lncRNA SNPs in Breast Cancer
GWAS initiative grant no. 1 U19 CA 148065 (DRIVE, part of the
GAME-ON initiative).
ACKNOWLEDGMENTS
We thank Joe Dennis for the technical assistance with the BCAC
data retrieval, Dr. Kristiina Aittomäki and research nurse Outi
Malkavaara for the help with the Helsinki patient data, Taru
Muranen for text editing and bioinformatical assistance, and Liisa
Pelttari for assistance in data analysis.
SUPPLEMENTARY MATERIAL




Amaral, P. P., Clark, M. B., Gascoigne, D. K., Dinger, M. E., and Mattick, J. S.
(2011). lncRNAdb: a reference database for long noncoding RNAs. Nucleic
Acids Res. 39, D146–D151.
Amos, C. I., Dennis, J., Wang, Z., Byun, J., Schumacher, F. R., Gayther, S. A.,
et al. (2017). The oncoarray consortium: a network for understanding the
genetic architecture of common cancers. Cancer Epidemiol. Biomarkers Prev.
261, 126–135.
Atlas, E., Stramwasser, M., Whiskin, K., and Mueller, C. R. (2000). GA-binding
protein alpha/beta is a critical regulator of the BRCA1 promoter. Oncogene
1915, 1933–1940. doi: 10.1038/sj.onc.1203516
Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W. J., Mattick, J. S.,
et al. (2004). Ultraconserved elements in the human genome. Science 304,
1321–1325. doi: 10.1126/science.1098119
Calin, G. A., Liu, C. G., Ferracin, M., Hyslop, T., Spizzo, R., Sevignani, C.,
et al. (2007). Ultraconserved regions encoding ncRNAs are altered in human
leukemias and carcinomas. Cancer Cell 123, 215–229. doi: 10.1016/j.ccr.2007.
07.027
Chen, G., Wang, Z., Wang, D., Qiu, C., Liu, M., Chen, X., et al. (2013).
LncRNADisease: a database for long-non-coding RNA-associated diseases.
Nucleic Acids Res. 41, D983–D986.
Collaborative Group on Hormonal Factors in Breast Cancer (2001). Familial breast
cancer: collaborative reanalysis of individual data from 52 epidemiological
studies including 58,209 women with breast cancer and 101,986 women
without the disease. Lancet 358, 1389–1399. doi: 10.1016/s0140-6736(01)
06524-2
Cui, P., Zhao, Y., Chu, X., He, N., Zheng, H., Han, J., et al. (2018). SNP rs2071095
in LincRNA H19 is associated with breast cancer risk. Breast Cancer Res. Treat.
171, 161–171. doi: 10.1007/s10549-018-4814-y
Curtis, C., Shah, S. P., Chin, S. F., Turashvili, G., Rueda, O. M., Dunning, M. J.,
et al. (2012). The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature 486, 346–352. doi: 10.1038/nature
10983
Dember, L. M., Kim, N. D., Liu, K. Q., and Anderson, P. (1996). Individual RNA
recognition motifs of TIA-1 and TIAR have different RNA binding specificities.
J. Biol. Chem. 271, 2783–2788. doi: 10.1074/jbc.271.5.2783
Dermitzakis, E. T., Reymond, A., and Antonarakis, S. E. (2005). Conserved non-
genic sequences - an unexpected feature of mammalian genomes. Nat. Rev.
Genet. 62, 151–157. doi: 10.1038/nrg1527
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al.
(2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis
of their gene structure, evolution, and expression. Genome Res. 22, 1775–1789.
doi: 10.1101/gr.132159.111
Deutsch, E., Jarrousse, S., Buet, D., Dugray, A., Bonnet, M. L., Vozenin-Brotons,
M. C., et al. (2003). Down-regulation of BRCA1 in BCR-ABL-expressing
hematopoietic cells. Blood 101, 4583–4588. doi: 10.1182/blood-2002-10-
3011
Eeles, R. A., Kote-Jarai, Z., Al Olama, A. A., Giles, G. G., Guy, M., Severi, G., et al.
(2009). Identification of seven new prostate cancer susceptibility loci through a
genome-wide association study. Nat. Genet. 41, 1116–1121.
Fabris, L., and Calin, G. A. (2017). Understanding the genomic ultraconservations:
T-UCRs and Cancer. Int. Rev. Cell. Mol. Biol. 333, 159–172. doi: 10.1016/bs.
ircmb.2017.04.004
Fernandez-Miranda, G., and Mendez, R. (2012). The CPEB-family of proteins,
translational control in senescence and cancer. Ageing Res. Rev. 114, 460–472.
doi: 10.1016/j.arr.2012.03.004
Fishilevich, S., Nudel, R., Rappaport, N., Hadar, R., Plaschkes, I., Iny Stein,
T., et al. (2017). GeneHancer: genome-wide integration of enhancers and
target genes in GeneCards. Database 2017:bax028. doi: 10.1093/database/
bax028
Ghoussaini, M., Pharoah, P. D. P., and Easton, D. F. (2013). Inherited genetic
susceptibility to breast cancer: the beginning of the end or the end of the
beginning? Am. J. Pathol. 183, 1038–1051.
Gibb, E. A., Vucic, E. A., Enfield, K. S., Stewart, G. L., Lonergan, K. M., Kennett,
J. Y., et al. (2011). Human cancer long non-coding RNA transcriptomes. PLoS
One 6:e25915. doi: 10.1371/journal.pone.0025915
Gilks, N., Kedersha, N., Ayodele, M., Shen, L., Stoecklin, G., Dember,
L. M., et al. (2004). Stress granule assembly is mediated by prion-like
aggregation of TIA-1. Mol. Biol. Cell 15, 5383–5398. doi: 10.1091/mbc.e04-08-
0715
Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A., and Skolnick, M. H. (1994).
Systematic population-based assessment of cancer risk in first-degree relatives
of cancer probands. J. Natl. Cancer Inst. 86, 1600–1608. doi: 10.1093/jnci/86.21.
1600
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J.,
et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state
to promote cancer metastasis. Nature 464, 1071–1076. doi: 10.1038/nature
08975
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., et al.
(2009). Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature 458, 223–227. doi: 10.1038/nature
07672
Hake, L. E., and Richter, J. D. (1994). CPEB is a specificity factor that mediates
cytoplasmic polyadenylation during Xenopus oocyte maturation. Cell 79, 617–
627. doi: 10.1016/0092-8674(94)90547-9
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-Andre, V., Sigova, A. A., et al.
(2013). Super-enhancers in the control of cell identity and disease. Cell 155,
934–947. doi: 10.1016/j.cell.2013.09.053
Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., and Abecasis, G. R.
(2012). Fast and accurate genotype imputation in genome-wide association
studies through pre-phasing. Nat. Genet. 44, 955–959. doi: 10.1038/ng.
2354
Howie, B. N., Donnelly, P., and Marchini, J. (2009). A flexible and accurate
genotype imputation method for the next generation of genome-wide
association studies. PLoS Genet. 5:e1000529. doi: 10.1371/journal.pone.
01000529
Hung, C. L., Wang, L. Y., Yu, Y. L., Chen, H. W., Srivastava, S., Petrovics, G.,
et al. (2014). A long noncoding RNA connects c-Myc to tumor metabolism.
Proc. Natl. Acad. Sci. U.S.A. 111, 18697–18702. doi: 10.1073/pnas.141566
9112
Jamshidi, M., Fagerholm, R., Khan, S., Aittomaki, K., Czene, K., Darabi, H., et al.
(2015). SNP-SNP interaction analysis of NF-kappaB signaling pathway on
breast cancer survival. Oncotarget 6, 37979–37994.
Johnson, A. D., Handsaker, R. E., Pulit, S. L., Nizzari, M. M., O’Donnell, C. J.,
and de Bakker, P. I. (2008). SNAP: a web-based tool for identification and
annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938–2939. doi:
10.1093/bioinformatics/btn564
Frontiers in Genetics | www.frontiersin.org 14 June 2020 | Volume 11 | Article 550
fgene-11-00550 June 30, 2020 Time: 12:37 # 15
Suvanto et al. lncRNA SNPs in Breast Cancer
Kapranov, P., Cheng, J., Dike, S., Nix, D. A., Duttagupta, R., Willingham, A. T.,
et al. (2007). RNA maps reveal new RNA classes and a possible function
for pervasive transcription. Science 316, 1484–1488. doi: 10.1126/science.113
8341
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M.,
et al. (2002). The human genome browser at UCSC. Genome Res. 12, 996–1006.
doi: 10.1101/gr.229102
Khan, S., Fagerholm, R., Rafiq, S., Tapper, W., Aittomaki, K., Liu, J., et al. (2015).
Polymorphism at 19q13.41 predicts breast cancer survival specifically after
endocrine therapy. Clin. Cancer Res. 2118, 4086–4096. doi: 10.1158/1078-0432.
ccr-15-0296
Kim, H. S., Headey, S. J., Yoga, Y. M., Scanlon, M. J., Gorospe, M., Wilce, M. C.,
et al. (2013). Distinct binding properties of TIAR RRMs and linker region. RNA
Biol. 104, 579–589. doi: 10.4161/rna.24341
Klinge, C. M. (2018). Non-Coding RNAs in breast cancer: intracellular and
intercellular communication. Noncoding RNA 4:40. doi: 10.3390/ncrna404
0040
Kretz, M., Siprashvili, Z., Chu, C., Webster, D. E., Zehnder, A., Qu, K., et al. (2013).
Control of somatic tissue differentiation by the long non-coding RNA TINCR.
Nature 493, 231–235. doi: 10.1038/nature11661
Li, J., Xue, Y., Amin, M. T., Yang, Y., Yang, J., Zhang, W., et al. (2019).
ncRNA-eQTL: a database to systematically evaluate the effects of SNPs on
non-coding RNA expression across cancer types. Nucleic Acids Res. 48,
D956–D963.
Li, Y., Willer, C. J., Ding, J., Scheet, P., and Abecasis, G. R. (2010). MaCH: using
sequence and genotype data to estimate haplotypes and unobserved genotypes.
Genet. Epidemiol. 34, 816–834. doi: 10.1002/gepi.20533
Li, Y., and Yuan, Y. (2017). Alternative RNA splicing and gastric cancer. Mutat.
Res. 773, 263–273. doi: 10.1016/j.mrrev.2016.07.011
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo,
M., et al. (2000). Environmental and heritable factors in the causation of cancer–
analyses of cohorts of twins from Sweden, Denmark, and Finland. Nat. Engl. J.
Med. 343, 78–85. doi: 10.1056/nejm200007133430201
Lu, R., Zhou, Z., Yu, W., Xia, Y., and Zhi, X. (2017). CPEB4 promotes cell
migration and invasion via upregulating Vimentin expression in breast cancer.
Biochem. Biophys. Res. Commun. 489, 135–141. doi: 10.1016/j.bbrc.2017.
05.112
Machiela, M. J., and Chanock, S. J. (2015). LDlink: a web-based application for
exploring population-specific haplotype structure and linking correlated alleles
of possible functional variants. Bioinformatics 31, 3555–3557. doi: 10.1093/
bioinformatics/btv402
Mathias, C., Zambalde, E. P., Rask, P., Gradia, D. F., and de Oliveira, J. C.
(2019). Long non-coding RNAs differential expression in breast cancer
subtypes: what do we know? Clin. Genet. 95, 558–568. doi: 10.1111/cge.
13502
Mattick, J. S. (2009). The genetic signatures of noncoding RNAs. PLoS Genet.
5:e1000459. doi: 10.1371/journal.pgen.1000459
Mavaddat, N., Pharoah, P. D., Michailidou, K., Tyrer, J., Brook, M. N., Bolla, M. K.,
et al. (2015). Prediction of breast cancer risk based on profiling with common
genetic variants. J. Natl. Cancer Inst. 107:djv036.
Mendez, R., and Richter, J. D. (2001). Translational control by CPEB: a
means to the end. Nat. Rev. Mol. Cell Biol. 2, 521–529. doi: 10.1038/3508
0081
Mercer, T. R., Dinger, M. E., and Mattick, J. S. (2009). Long non-coding RNAs:
insights into functions. Nat. Rev. Genet. 10, 155–159.
Mestdagh, P., Fredlund, E., Pattyn, F., Rihani, A., Van Maerken, T., Vermeulen, J.,
et al. (2010). An integrative genomics screen uncovers ncRNA T-UCR functions
in neuroblastoma tumours. Oncogene 29, 3583–3592. doi: 10.1038/onc.2010.
106
Meyer, K. B., Maia, A. T., O’Reilly, M., Ghoussaini, M., Prathalingam, R., Porter-
Gill, P., et al. (2011). A functional variant at a prostate cancer predisposition
locus at 8q24 is associated with PVT1 expression. PLoS Genet. 7:e1002165.
doi: 10.1371/journal.pgen.1002165
Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis, J., Lush, M. J., et al.
(2015). Genome-wide association analysis of more than 120,000 individuals
identifies 15 new susceptibility loci for breast cancer. Nat. Genet. 47, 373–380.
doi: 10.1038/ng.3242
Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J.,
Milne, R. L., et al. (2013). Large-scale genotyping identifies 41 new loci
associated with breast cancer risk. Nat. Genet. 45, 353–361. doi: 10.1038/ng.
2563
Michailidou, K., Lindstrom, S., Dennis, J., Beesley, J., Hui, S., Kar, S., et al. (2017).
Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94.
doi: 10.1038/nature24284
Milne, R. L., Kuchenbaecker, K. B., Michailidou, K., Beesley, J., Kar, S., Lindstrom,
S., et al. (2017). Identification of ten variants associated with risk of estrogen-
receptor-negative breast cancer. Nat. Genet. 49, 1767–1778. doi: 10.1038/ng.
3785
Nielsen, F. C., van Overeem Hansen, T., and Sorensen, C. S. (2016). Hereditary
breast and ovarian cancer: new genes in confined pathways. Nat. Rev. Cancer
16, 599–612. doi: 10.1038/nrc.2016.72
O’Connell, J., Gurdasani, D., Delaneau, O., Pirastu, N., Ulivi, S., Cocca, M., et al.
(2014). A general approach for haplotype phasing across the full spectrum
of relatedness. PLoS Genet. 10:e1004234. doi: 10.1371/journal.pgen.100
4234
Park, H. J., Ji, P., Kim, S., Xia, Z., Rodriguez, B., Li, L., et al. (2018). 3′
UTR shortening represses tumor-suppressor genes in trans by disrupting
ceRNA crosstalk. Nat. Genet. 50, 783–789. doi: 10.1038/s41588-018-
0118-8
Podszywalow-Bartnicka, P., Wolczyk, M., Kusio-Kobialka, M., Wolanin, K.,
Skowronek, K., Nieborowska-Skorska, M., et al. (2014). Downregulation of
BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-
mediated suppression of translation. Cell. Cycle 13, 3727–3741. doi: 10.4161/
15384101.2014.965013
R Core Team (2013). R: A Language And Environment For Statistical Computing.
Vienna: R Foundation for Statistical Computing.
Riaz, M., Berns, E. M., Sieuwerts, A. M., Ruigrok-Ritstier, K., de Weerd, V.,
Groenewoud, A., et al. (2012). Correlation of breast cancer susceptibility loci
with patient characteristics, metastasis-free survival, and mRNA expression of
the nearest genes. Breast Cancer Res. Treat. 133, 843–851. doi: 10.1007/s10549-
011-1663-3
Richter, J. D. (2007). CPEB: a life in translation. Trends Biochem. Sci. 32, 279–285.
doi: 10.1016/j.tibs.2007.04.004
Scaruffi, P. (2011). The transcribed-ultraconserved regions: a novel class of long
noncoding RNAs involved in cancer susceptibility. Sci. World J. 11, 340–352.
doi: 10.1100/tsw.2011.35
Shabalin, A. A. (2012). Matrix eQTL: ultra fast eQTL analysis via large
matrix operations. Bioinformatics 28, 1353–1358. doi: 10.1093/bioinformatics/
bts163
Sun, H. T., Wen, X., Han, T., Liu, Z. H., Li, S. B., Wang, J. G., et al. (2015).
Expression of CPEB4 in invasive ductal breast carcinoma and its prognostic
significance. Onco Targets Ther. 8, 3499–3506.
Terracciano, D., Terreri, S., de Nigris, F., Costa, V., Calin, G. A., and Cimmino,
A. (2017). The role of a new class of long noncoding RNAs transcribed from
ultraconserved regions in cancer. Biochim. Biophys. Acta 1868, 449–455. doi:
10.1016/j.bbcan.2017.09.001
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015).
Global cancer statistics, 2012CA Cancer. J. Clin. 65, 87–108. doi: 10.3322/caac.
21262
Turnbull, C., Ahmed, S., Morrison, J., Pernet, D., Renwick, A., Maranian, M.,
et al. (2010). Genome-wide association study identifies five new breast cancer
susceptibility loci. Nat. Genet. 42, 504–507.
Wang, K. C., and Chang, H. Y. (2011). Molecular mechanisms of long noncoding
RNAs. Mol. Cell 43, 904–914. doi: 10.1016/j.molcel.2011.08.018
Wang, P., Xue, Y., Han, Y., Lin, L., Wu, C., Xu, S., et al. (2014). The STAT3-binding
long noncoding RNA lnc-DC controls human dendritic cell differentiation.
Science 344, 310–313. doi: 10.1126/science.1251456
Wolanin, K., Magalska, A., Kusio-Kobialka, M., Podszywalow-Bartnicka, P., Vejda,
S., McKenna, S. L., et al. (2010). Expression of oncogenic kinase Bcr-Abl
impairs mitotic checkpoint and promotes aberrant divisions and resistance to
microtubule-targeting agents. Mol. Cancer Ther. 9, 1328–1338. doi: 10.1158/
1535-7163.mct-09-0936
Wu, L., Shi, W., Long, J., Guo, X., Michailidou, K., Beesley, J., et al.
(2018). A transcriptome-wide association study of 229,000 women identifies
Frontiers in Genetics | www.frontiersin.org 15 June 2020 | Volume 11 | Article 550
fgene-11-00550 June 30, 2020 Time: 12:37 # 16
Suvanto et al. lncRNA SNPs in Breast Cancer
new candidate susceptibility genes for breast cancer. Nat. Genet. 50,
968–978.
Xing, Z., Lin, A., Li, C., Liang, K., Wang, S., Liu, Y., et al. (2014). lncRNA directs
cooperative epigenetic regulation downstream of chemokine signals. Cell 159,
1110–1125. doi: 10.1016/j.cell.2014.10.013
Yang, F., Huo, X. S., Yuan, S. X., Zhang, L., Zhou, W. P., Wang, F., et al.
(2013). Repression of the long noncoding RNA-LET by histone deacetylase
3 contributes to hypoxia-mediated metastasis. Mol. Cell 49, 1083–1096. doi:
10.1016/j.molcel.2013.01.010
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., et al.
(2018). Ensembl 2018. Nucleic Acids Res. 46, D754–D761.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Suvanto, Beesley, Blomqvist, Chenevix-Trench, Khan and
Nevanlinna. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 16 June 2020 | Volume 11 | Article 550
